Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring

#	Paper	IF	Citations
33	Lack of penetration of amikacin into saliva of tuberculosis patients. *European Respiratory Journal*, **2018**, 51,	13.6	6
32	Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	13
31	Drugs in tuberculosis and leprosy. *Side Effects of Drugs Annual*, **2019**, 41, 321-338	0.2	3
30	Therapeutic Drug Monitoring: The Need for Practical Guidance. *Clinical Infectious Diseases*, **2019**, 68, 1065-1066	11.6	16
29	Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.. *Clinical Mass Spectrometry*, **2019**, 14 Pt A, 34-45	1.9	7
28	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. *Clinical Infectious Diseases*, **2020**, 70, 1774-1780	11.6	32
27	Saliva sampling: Methods and devices. An overview. *TrAC - Trends in Analytical Chemistry*, **2020**, 124, 115781	13.6	68
26	Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future. *Infection and Drug Resistance*, **2020**, 13, 2795-2800	4.2	5
25	Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. *European Respiratory Journal*, **2020**, 56,	13.6	3
24	PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva. *Pharmacology Research and Perspectives*, **2020**, 8, e00574	3.1	1
23	Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. *European Respiratory Journal*, **2020**, 55,	13.6	7
22	A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 423-429	5.1	5
21	Overview of biopharmaceutics and pharmacokinetics. **2021**, 1-16		
20	Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. *Brazilian Dental Journal*, **2021**, 32, 3-8	1.9	0
19	Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 1547-1552	5.1	4
18	From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 928-941	6.1	30
17	Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis. *European Respiratory Journal*, **2021**, 57,	13.6	

16	TDM of Anti-infective Drugs: Implementation Strategies for Three Different Scenarios. *Therapeutic Drug Monitoring*, **2021**, 44,	3.2	0
15	Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. *Therapeutic Drug Monitoring*, **2021**,	3.2	2
14	Monitoring during and after tuberculosis treatment. 308-325		1
13	A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods. *Drug Metabolism and Personalized Therapy*, **2020**,	2	
12	Comparison of free plasma versus saliva mycophenolic acid exposure following mycophenolate mofetil administration in adult kidney transplant recipients. *Clinical Biochemistry*, **2021**, 100, 78-78	3.5	1
11	Has the Time Come for Systematic Therapeutic Drug Monitoring of First-line and WHO Group A Anti-tuberculosis Drugs?. *Therapeutic Drug Monitoring*, **2021**,	3.2	
10	Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Cancer Patients.. *Therapeutic Drug Monitoring*, **2022**,	3.2	0
9	Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19.		
8	A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods. *Drug Metabolism and Personalized Therapy*, **2020**, 35,	2	
7	Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management. *Pharmaceutics*, **2022**, 14, 990	6.4	0
6	Simple simultaneous determination of moxifloxacin and metronidazole in complex biological matrices. *RSC Advances*, **2022**, 12, 15694-15704	3.7	0
5	Assessing physical and chemical properties of saliva among tuberculosis patients on anti-tuberculosis treatment- An observational study. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **2022**, 100322	2.1	
4	Saliva as Blood Alternative in Therapeutic Monitoring of Teriflunomide Development and Validation of the Novel Analytical Method. **2022**, 23, 9544		0
3	A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. 9,		0
2	Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis. Volume 15, 6839-6852		0
1	Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review. **2023**, 62, 375-398		0